Product
Contrave
Aliases
Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl
Name
Contrave
INN Name
naltrexone hydrochloride and bupropion hydrochloride
FDA Approved
Yes
5 clinical trials
1 organization
6 indications
1 document
Indication
Breast CancerIndication
ObesityIndication
Stimulant UseIndication
RelapseIndication
Cognitive FunctionIndication
ADHDClinical trial
A Phase II Single Arm Adaptive Weight Loss Study in Women With Early Stage Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-01-10
Clinical trial
Relapse Prevention in Stimulant Use DisorderStatus: Withdrawn, Estimated PCD: 2025-01-11
Clinical trial
Trial Evaluating Effectiveness of Contrave (Naltrexone HCl / Bupropion HCl) for Weight Maintenance in Adults With BMI ≥ 27 Kg/m2, After 6 Month Intensive Behavior Modification Program: Contrave Obesity Trials (COR) Weight Maintenance StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized Controlled Trial Evaluating the Effectiveness of Contrave (Naltrexone HCl and Bupropion HCl) in Patients Who Have Weight Recidivism Following Bariatric Surgery: Contrave Obesity Trials (COR) Weight Regain StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
Assessment of and Treatment Applied to Food Addiction to Encourage Self-Management of Obesity in a Rural Healthy Behaviors ClinicStatus: Completed, Estimated PCD: 2022-06-01
Document
DailyMed Label: ContraveOrganization
Nalpropion Pharmaceuticals LLC